首页 > 按专业查询名词 > 查询PubMed相关文献
名词信息
Pubmed相关的文献
multiple sclerosis, primary progressive相关文献:
Diagnosis and treatment of progressive multiple sclerosis: A position paper.
Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, Airas L, Oreja-Guevara C.
Eur J Neurol. 2023 Jan;30(1):9-21. doi: 10.1111/ene.15593. Epub 2022 Oct 25.
PMID:36209464
Progressive Multiple Sclerosis.
Amezcua L.
Continuum (Minneap Minn). 2022 Aug 1;28(4):1083-1103. doi: 10.1212/CON.0000000000001157.
PMID:35938658
Progressive multiple sclerosis: pathology and pathogenesis.
Lassmann H, van Horssen J, Mahad D.
Nat Rev Neurol. 2012 Nov 5;8(11):647-56. doi: 10.1038/nrneurol.2012.168. Epub 2012 Sep 25.
PMID:23007702
Primary-progressive multiple sclerosis.
Miller DH, Leary SM.
Lancet Neurol. 2007 Oct;6(10):903-12. doi: 10.1016/S1474-4422(07)70243-0.
PMID:17884680
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives.
Gajofatto A, Turatti M, Benedetti MD.
Expert Rev Neurother. 2017 Apr;17(4):393-406. doi: 10.1080/14737175.2017.1257385. Epub 2016 Nov 15.
PMID:27813441
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.
Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.
PMID:19847908
Emerging drugs for primary progressive multiple sclerosis.
Narayan RN, Forsthuber T, Stüve O.
Expert Opin Emerg Drugs. 2018 Jun;23(2):97-110. doi: 10.1080/14728214.2018.1463370. Epub 2018 Apr 24.
PMID:29638150
Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression.
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A.
Int J Mol Sci. 2024 Aug 11;25(16):8751. doi: 10.3390/ijms25168751.
PMID:39201438
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE.
EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22.
PMID:37354600
[Primary Progressive Multiple Sclerosis].
Kufukihara K, Nakahara J.
Brain Nerve. 2021 May;73(5):458-465. doi: 10.11477/mf.1416201786.
PMID:34006676
© Copyright 2021 鸿泰茂源  版权所有All Rights Reserved京ICP备11040441号-3